Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2026 | Findings from a Phase Ib/II trial assessing azacitidine, venetoclax & ivosidenib in IDH1-mutated AML

Akriti Jain • 27 Jun 2026
ASCO 2026
Acute Myeloid Leukemia Leukemia Azacitidine Ivosidenib Venetoclax
VIALE-A

Akriti Jain, MD, Cleveland Clinic, Cleveland, OH, shares insights into a Phase Ib/II trial of azacitidine, venetoclax, and ivosidenib in IDH1-mutated acute myeloid leukemia (AML). Dr Jain highlights high overall and composite response rates, exceeding those reported in previous studies, including the VIALE-A study (NCT02993523), and emphasizes that these outcomes may help to improve patient eligibility for transplant. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Akriti Jain

Key diagnostic and therapeutic challenges in TP53-mutated MDS, AML, and MPNs
1:56
Key diagnostic and therapeutic challenges in TP53-mutated MDS, AML, and MPNs
Akriti Jain • 27 Jun 2026
The optimal frequency and timing of NGS testing in MPNs
1:51
The optimal frequency and timing of NGS testing in MPNs
Akriti Jain • 27 May 2026
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
2:21
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
Akriti Jain • 27 May 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals